Britain recently signed an agreement for the usage of up to 60 million doses of a potential COVID-19 vaccine, developed by Sanofi and GlaxoSmithKline.
Britain has secured four deals of vaccine supply for COVID-19. Minister Alok Sharma said that it is very important that they secure early access to many types of vaccines to increase their chances of finding the one that works.
Sanofi and GSK have confirmed that regulatory approval for their vaccine could be achieved by the first half of 2021 if clinical data shows good results.
Just previously, Britain completed deals for 30 million doses of an experimental BioNtech and Pfizer vaccine, and a deal in principle for 60 million doses of Valneva’s potential shot, which followed a previously announced deal for 100 million doses of an experimental Oxford and AstraZeneca vaccine.
The EU and the United States have secured $ 400 million and $ 300 million doses of the Oxford and AstraZeneca vaccine respectively, while the US government has also agreed to purchase $ 100 million doses of the Pfizer and BioNtech vaccine, with an option for $ 500 million more.
The Sanofi and GSK vaccine utilizes Sanofi’s S-protein COVID-19 antigen and GSK’s pandemic adjuvant technology, and the first clinical trials are expected to commence in September.